WEKO3
アイテム
{"_buckets": {"deposit": "0ae5575f-3531-4820-af2a-bbda4af6f468"}, "_deposit": {"created_by": 2, "id": "23169", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "23169"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00023169", "sets": ["74"]}, "author_link": ["97835", "97836", "97832", "97833", "97834"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2003-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "993", "bibliographicPageStart": "988", "bibliographicVolumeNumber": "26", "bibliographic_titles": [{"bibliographic_title": "Biological \u0026 Pharmaceutical Bulletin"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We have examined the influence of liver disease on drug absorption from the liver surface membrane, regarded as the first barrier for drug targeting to the liver. The main purpose of this study is to examine the possibility of direct liver surface application as a drug targeting method. We employed rats intoxicated with carbon tetrachloride (CCl4) or D-galactosamine (GAL) as the liver disease model, and examined drug absorption characteristics after application to the liver surface, by utilizing a cylindrical diffusion cell. In the liver-intoxicated rats, about 90% of a low molecular weight drug, phenolsulfonphthalein (PSP), as a model was absorbed from the liver surface in 6 h, similar to the normal rats (no treatment). Although the absorption rate was increased in the CCl4 group, whereas slightly retarded absorption was observed in GAL group, there should be no serious problem for the clinical use of liver surface application. The PSP absorption from the liver surface in the CCl4 group was indicated to obey first-order kinetics by elimination profile from the diffusion cell. The first-order absorption rate constant Ka values of PSP from the liver surface, obtained by a compartment model and elimination profile, were increased 1.3-fold in the CCl4 group compared to the control. Moreover, we performed drug application to the liver surface in the peritoneal cavity to assume clinical use. The Ka of PSP in the CCl4 group was about 4-fold larger than in the normal group, implying the importance of estimating changes in peritoneal drug absorption as a result of liver disease. Consequently, it is expected that there will be no marked decline in the absorption rate from the liver surface in a liver disease state, leading us to apply this administration method for liver targeting.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Biological \u0026 Pharmaceutical Bulletin v.26(7) p.988-993, 2003", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Pharmaceutical Society of Japan"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "12843624", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1248/bpb.26.988", "subitem_relation_type_select": "DOI"}}]}, "item_2_relation_42": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "http://dx.doi.org/10.1248/bpb.26.988"}]}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10885497", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09186158", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1347-5215", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nishida, Koyo"}], "nameIdentifiers": [{"nameIdentifier": "97832", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Honda, Tominori"}], "nameIdentifiers": [{"nameIdentifier": "97833", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakashima, Mikiro"}], "nameIdentifiers": [{"nameIdentifier": "97834", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sasaki, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "97835", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Junzo"}], "nameIdentifiers": [{"nameIdentifier": "97836", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "BPBul26_988.pdf", "filesize": [{"value": "84.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 84300.0, "url": {"label": "BPBul26_988.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/23169/files/BPBul26_988.pdf"}, "version_id": "bb6784e7-2ca4-493e-a9e0-29e2063e93e7"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "drug targeting", "subitem_subject_scheme": "Other"}, {"subitem_subject": "liver disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "absorption", "subitem_subject_scheme": "Other"}, {"subitem_subject": "organ surface", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Influence of Liver Disease on Phenolsulfonphthalein Absorption from Liver Surface to Examine Possibility of Direct Liver Surface Application for Drug Targeting", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Influence of Liver Disease on Phenolsulfonphthalein Absorption from Liver Surface to Examine Possibility of Direct Liver Surface Application for Drug Targeting"}]}, "item_type_id": "2", "owner": "2", "path": ["74"], "permalink_uri": "http://hdl.handle.net/10069/8384", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-10-12"}, "publish_date": "2007-10-12", "publish_status": "0", "recid": "23169", "relation": {}, "relation_version_is_last": true, "title": ["Influence of Liver Disease on Phenolsulfonphthalein Absorption from Liver Surface to Examine Possibility of Direct Liver Surface Application for Drug Targeting"], "weko_shared_id": -1}
Influence of Liver Disease on Phenolsulfonphthalein Absorption from Liver Surface to Examine Possibility of Direct Liver Surface Application for Drug Targeting
http://hdl.handle.net/10069/8384
http://hdl.handle.net/10069/83846260a78d-a7c5-408b-89ff-c28dadf2561b
名前 / ファイル | ライセンス | アクション |
---|---|---|
BPBul26_988.pdf (84.3 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-10-12 | |||||
タイトル | ||||||
タイトル | Influence of Liver Disease on Phenolsulfonphthalein Absorption from Liver Surface to Examine Possibility of Direct Liver Surface Application for Drug Targeting | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug targeting | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | liver disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | absorption | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | organ surface | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Nishida, Koyo
× Nishida, Koyo× Honda, Tominori× Nakashima, Mikiro× Sasaki, Hitoshi× Nakamura, Junzo |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We have examined the influence of liver disease on drug absorption from the liver surface membrane, regarded as the first barrier for drug targeting to the liver. The main purpose of this study is to examine the possibility of direct liver surface application as a drug targeting method. We employed rats intoxicated with carbon tetrachloride (CCl4) or D-galactosamine (GAL) as the liver disease model, and examined drug absorption characteristics after application to the liver surface, by utilizing a cylindrical diffusion cell. In the liver-intoxicated rats, about 90% of a low molecular weight drug, phenolsulfonphthalein (PSP), as a model was absorbed from the liver surface in 6 h, similar to the normal rats (no treatment). Although the absorption rate was increased in the CCl4 group, whereas slightly retarded absorption was observed in GAL group, there should be no serious problem for the clinical use of liver surface application. The PSP absorption from the liver surface in the CCl4 group was indicated to obey first-order kinetics by elimination profile from the diffusion cell. The first-order absorption rate constant Ka values of PSP from the liver surface, obtained by a compartment model and elimination profile, were increased 1.3-fold in the CCl4 group compared to the control. Moreover, we performed drug application to the liver surface in the peritoneal cavity to assume clinical use. The Ka of PSP in the CCl4 group was about 4-fold larger than in the normal group, implying the importance of estimating changes in peritoneal drug absorption as a result of liver disease. Consequently, it is expected that there will be no marked decline in the absorption rate from the liver surface in a liver disease state, leading us to apply this administration method for liver targeting. | |||||
書誌情報 |
Biological & Pharmaceutical Bulletin 巻 26, 号 7, p. 988-993, 発行日 2003-07 |
|||||
出版者 | ||||||
出版者 | Pharmaceutical Society of Japan | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09186158 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1347-5215 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA10885497 | |||||
PubMed番号 | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | 12843624 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1248/bpb.26.988 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
関係URI | ||||||
関連名称 | http://dx.doi.org/10.1248/bpb.26.988 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Biological & Pharmaceutical Bulletin v.26(7) p.988-993, 2003 |